clinical trial · NCT05834868
Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 2 Diabetes
Tonghua Dongbao Pharmaceutical Co.,Ltd·phase3·completed·n = 1,040
Type 2 DiabetesTHDB0206 InjectionInsulin Lispro Injection
brief summary
This is a 26-week randomized, open-label, multicenter, active-controlled parallel group trial. The purpose of this study is to compare efficacy and safety of THDB0206 injection with insulin lispro injection combined with insulin glargine injection U-100 in Chinese participants with T2DM.
started
May 6, 2022
primary completion
Dec 10, 2024
completion
Dec 31, 2024
last updated
Dec 22, 2025
official title
A Phase 3, Randomized, Open-Label, Multicenter, Active-controlled Trial Comparing Efficacy and Safety of THDB0206 Injection With Insulin Lispro Injection Combined With Insulin Glargine Injection U-100 in Chinese Participants With Type 2 Diabetes
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol